Glicentin, EIA - Cosmo Bio Co.,Ltd.

Antibodies

>

Glicentin, EIA

Catalog No.: YII-YK111-EX
Size: 1KIT
Price: ¥76000
$1014
antigen/source: Glicentin
Label: Unlabeled
Application: Enzyme Immunoassay
catalog info: Catalog 2012-p111
Storage: 4C
@
Immunogen: Rat
Reacts with: Rat
Measurement Range: 0.206 - 50 pmol/mL
Purpose: This EIA kit is used for quantitative determination of rat.. glicentin in plasma sample. The kit is characterized for sensitive quantification, high specificity and no influence with other components in plasma and needlessness of sample pre-treatment. Glicentin standard used in the kit is a highly purified synthetic product...
component: Antibody: X
Plate: X
Coating: X
Control: -
Standard: X
Labeling: X
Substrate: X
Others: X
1. Antibody coated plate 1 plate (96 wells)
2. Glicentin standard 1 vial
3. Labeled antigen 1 vial
4. Glicentin antibody 1 bottle (6 mL )
5. SA-HRP solution 1 bottle (12 mL )
6. Substrate buffer 1 bottle (26 mL )
7. OPD tablet 2 tablets
8. Stopping solution 1 bottle (12 mL )
9. Buffer solution 1 bottle (10 mL )
10. Washing solution 1 bottle (50 mL )
11. Adhesive foil 3 sheets

Other:

 Supplementary 
Competitive
 Applicable sample 
Plasma
[Other]
Glicentin is a 69-amino-acid peptide containing glucagon and oxyntomodulin sequences in the molecule. It is suggested that glicentin and oxyntomodulin are produced in the intestinalL-cells and glucagon in A-cells in the pancreas, these peptides are derived from a common precursor by two different tissue-specific processing pathways. In 1983, the amino acid sequence of human glicentin was deduced by Bell et al. from the genomicsequence of human preproglucagon. Glicentin is a major form of gut glucagon-like immunoreactants (Gut GLIs).
In mammalian small intestine, proglucagon is processed into glicentin, oxyntomodulin, and glucagon like peptide 1(GLP-1) and glucagon-like peptide 2 (GLP-2). GLP-1(7-37) and GLP-1(7-36)amide have been isolated from the intestine and pancreas. It has been known that the GLP-1 sequence is well conserved between species in all mammals studied. Using synthetic peptides, several investigators have demonstrated that in contrast to GLP-1 (1-37), truncated GLP-1(7-36)amide and GLP-1(7-37) have several physiological effects. However, the physiological role of glicentin, a major gut glucagon, is still unclear. It has been known that the circulating level of plasma glicentin-like peptides increases significantly nutrient ingestion.


Reference:

•  Kusakabe T, Ebihara K, Sakai T, Miyamoto L, Aotani D, Yamamoto Y, Yamamoto-Kataoka S, Aizawa-Abe M, Fujikura J, Hosoda K, Nakao K. Am J Physiol Endocrinol Metab. 2012 Jan 24.
•  Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T, Fukami A, Hamada Y, Inagaki N, SeinoY, Drucker DJ, Oiso Y, Nakamura J. Diabetes. 2011 Sep;60(9):2397-406. Epub 2011 Aug 1
•  Kimura K, Yamada T, Matsumoto M, Kido Y, Hosooka T, Asahara S, Matsuda T, Ota T, Watanabe H, Sai Y, Miyamoto K, Kaneko S, Kasuga M, Inoue H. Diabetes. 2012 Jan;61(1):61-73. Epub 2011 Nov 28.
•  Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, Takiyama Y, Makino Y, Abiko A, Kieffer TJ, Haneda M. Diabetologia. 2011 Nov 10.
•  Ezaki J, Matsumoto N, Takeda-Ezaki M, Komatsu M, Takahashi K, Hiraoka Y, Taka H, Fujimura T, Takehana K, Yoshida M, Iwata J, Tanida I, Furuya N, Zheng DM, Tada N, Tanaka K, Kominami E, Ueno T. Autophagy. 2011 Jul;7(7):727-36.
•  Onoue S, Kuriyama K, Uchida A, Mizumoto T, Yamada S. Pharm Res. 2011 May;28(5):1157-66.
•  Jung EJ, Kim SC, Wee YM, Kim YH, Choi MY, Jeong SH, Lee J, Lim DG, Han DJ. Cytotherapy. 2011 Jan;13(1):19-29.
•  Shimamura M, Karasawa H, Sakakibara S, Shinagawa A. Biochem Biophys Res Commun. 2010 Oct 8;401(1):79-84. Epub 2010 Sep 15.
•  Kasahara H, Muto S, Motokawa Y, Arisaka N, Kobayashi S, Souma S, Kuroda J. J Toxicol Sci. 2010;35(5):779-84.
•  Niimi K, Takahashi E, Itakura C. Comp Med. 2009 Oct;59(5):431-6.
•  Jeong H, Kwon HJ, Kim MK. Nutr Res Pract. 2009 Spring;3(1):23-30.
•  Yamanaka M, Itakura Y, Tsuchida A, Nakagawa T, Noguchi H, Taiji M. Diabetes Obes Metab. 2007 Nov;9(6):879-88.
•  Doi M, Yamaoka I, Nakayama M, Sugahara K, Yoshizawa F. Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1683-93.
•  Hamasaki A, Yamada Y, Kurose T, Ban N, Nagashima K, Takahashi A, Fujimoto S, Shimono D, Fujiwara M, Toyokuni S, Seino Y, Inagaki N. Biochem Biophys Res Commun. 2007 Feb 2;353(1):40-6.
•  Ishikawa T, Mizunoya W, Shibakusa T, Inoue K, Fushiki T. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1151-9.
•  Yamanaka M, Itakura Y, Inoue T, Tsuchida A, Nakagawa T, Noguchi H, Taiji M. Metabolism. 2006 Oct;55(10):1286-92.
•  Pereverzev A, Salehi A, Mikhna M, Renstrom E, Hescheler J, Weiergraber M, Smyth N, Schneider T. Eur J Pharmacol. 2005 Mar 21;511(1):65-72.
•  Maeda N, Funahashi T, Hibuse T, Nagasawa A, Kishida K, Kuriyama H, Nakamura T, Kihara S, Shimomura I, Matsuzawa Y. Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17801-6.
•  Zhou H, Tran PO, Yang S, Zhang T, LeRoy E, Oseid E, Robertson RP. Diabetes. 2004 Jun;53(6):1482-7.
 
>